XPENG Announces Vehicle Delivery Results for May 2025
30,000+ vehicles delivered monthly for seventh consecutive month
GUANGZHOU, China, June 01, 2025 (GLOBE NEWSWIRE) — XPeng Inc. ('XPENG' or the 'Company,' NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle ('Smart EV') company, today announced its vehicle delivery results for May 2025.
In May 2025, XPENG delivered 33,525 Smart EVs, representing growth of 230% year-over-year, surpassing 30,000 units for the seventh consecutive month. For the first five months of 2025, XPENG delivered 162,578 Smart EVs, marking a 293% increase compared to the same period last year.
On May 28th, the Company launched the MONA M03 Max. MONA M03 Max lowers the entry barrier for urban AI smart driving to the 150,000 RMB range for the first time, making advanced vehicle technology more accessible to younger users. The MONA M03 Max is also the first XPENG model equipped with the AI Tianji XOS 5.7.0, offering over 300 new features.
XNGP achieved a monthly active user penetration rate of 85% in urban driving in May 2025. Notably, the XPENG MONA M03 Max debuted the application of human-machine co-driving, enabling both ADAS and drivers to share control, providing a seamless collaboration between manual driving and smart driving.
About XPENG
XPENG is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers' mobility experience, XPENG develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Shenzhen, Silicon Valley and San Diego. The Company's Smart EVs are mainly manufactured at its plants in Zhaoqing and Guangzhou, Guangdong province. For more information, please visit https://www.xpeng.com/.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates' and similar statements. Statements that are not historical facts, including statements about XPENG's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG's goal and strategies; XPENG's expansion plans; XPENG's future business development, financial condition and results of operations; the trends in, and size of, China's EV market; XPENG's expectations regarding demand for, and market acceptance of, its products and services; XPENG's expectations regarding its relationships with customers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG's filings with the United States Securities and Exchange Commission. All information provided in this announcement is as of the date of this announcement, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Contacts:
For Investor Enquiries:
IR Department XPeng Inc.
Email: [email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合
Yahoo
40 minutes ago
- Yahoo
This Top Warren Buffett Stock Continues to Deliver an Impressive Performance
Key Points Occidental Petroleum is one of Berkshire Hathaway's largest holdings. The oil company recently reported solid second-quarter results. It's making excellent progress on its plans to repay debt and grow shareholder value. 10 stocks we like better than Occidental Petroleum › Warren Buffett's company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), continues to be a big believer in Occidental Petroleum (NYSE: OXY). It's easy to see why when looking at the oil giant's recently reported second-quarter results. The company delivered strong performance across the board despite lower oil and gas prices during the period. This consistent execution, even amid market volatility, gives Occidental Petroleum a solid foundation to grow shareholder value for Berkshire Hathaway and other investors in the years ahead. Drilling down into Occidental Petroleum's second-quarter results Occidental Petroleum produced $396 million, or $0.39 per share, of adjusted income during the second quarter. That was down from the $860 million, or $0.87 per share, it earned in the first quarter. The culprit was lower commodity prices. Occidental posted $934 million of pre-tax income in its oil and gas segment, down from $1.7 billion in the first quarter, due primarily to lower oil and gas prices. The average global price of crude oil was 10% below the first quarter's level, while the price of domestic natural gas tumbled 45%. Despite these lower prices, Occidental delivered higher volumes and strong results from its midstream and marketing segment. The company produced 1.4 million barrels of oil equivalent (BOE) per day, exceeding the mid-point of its guidance, while midstream and marketing earnings came in above the high-end of expectations. The company's chemicals business (OxyChem) also delivered solid results that were on par with its first-quarter performance. Additionally, strong well performance and enhanced operational efficiency supported robust cash generation. Operating cash flow before working capital adjustments was $2.6 billion, and free cash flow totaled $700 million, both slightly lower than the previous quarter. More progress on its debt-reduction plan Occidental Petroleum used its healthy free cash flow to pay its dividend and reduce debt. The company also continued to sell noncore assets to accelerate its debt-reduction efforts. It has secured $950 million of additional asset sales since the start of the second quarter. Those sales included $370 million of noncore and select non-operating Permian Basin upstream assets that closed during the quarter. Occidental also recently agreed to sell some gas-gathering assets in the Midland Basin to midstream company Enterprise Products Partners for $580 million. Those sales added to the $1.3 billion of noncore-asset sales it closed during the first quarter. The company has now agreed to sell $4 billion of assets since announcing its deal for CrownRock in late 2023, which has it closing in on the low end of its $4.5 billion to $6 billion target range. The energy company has used a combination of excess free cash and asset-sale proceeds to repay $3 billion of debt so far this year. Since July 2024, it has retired $7.5 billion of debt, saving it $410 million in annual interest expenses. The company has now significantly exceeded its target of delivering at least $4.5 billion of debt reduction within a year of closing its CrownRock deal. More positive catalysts ahead Occidental expects to continue using its excess free cash flow after paying dividends and noncore-asset sales to repay debt. It still has approximately $1.6 billion of 2026 debt maturities to address, as well as another $1.5 billion coming due in 2027. The company shouldn't have a problem paying off that debt, given the anticipated surge in its free cash flow from non-oil sources. The company estimates that a combination of interest expense savings, incremental earnings from upcoming chemicals projects, and midstream contract expirations will boost its free cash flow by $1 billion in 2026 and by an additional $500 million in 2027. As its debt continues to fall, Occidental will be positioned to return more cash to investors, beyond its dividend. It plans to eventually resume share repurchases and the redemption of Berkshire's preferred equity investment that it made in 2019 to support the company's acquisition of Anadarko Petroleum. A well-oiled machine Warren Buffett's Berkshire Hathaway has made a major bet on Occidental's ability to execute its plans to grow shareholder value. The company owns nearly 27% of the oil company's outstanding shares. That position is worth almost $12 billion (approximately 4% of Berkshire's investment portfolio), making it the seventh-largest holding. Occidental's strong second-quarter showing and progress on its debt-reduction plan prove that Buffett's company has made a smart investment. The oil company is in an excellent position to grow shareholder value in the future, despite the continued volatility of crude oil prices. Should you buy stock in Occidental Petroleum right now? Before you buy stock in Occidental Petroleum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Occidental Petroleum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Matt DiLallo has positions in Berkshire Hathaway and Enterprise Products Partners. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends Enterprise Products Partners and Occidental Petroleum. The Motley Fool has a disclosure policy. This Top Warren Buffett Stock Continues to Deliver an Impressive Performance was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Primo Brands Second Quarter 2025 Earnings: Misses Expectations
Explore Primo Brands's Fair Values from the Community and select yours Primo Brands (NYSE:PRMB) Second Quarter 2025 Results Key Financial Results Revenue: US$1.73b (up 32% from 2Q 2024). Net income: US$30.5m (down 44% from 2Q 2024). Profit margin: 1.8% (down from 4.1% in 2Q 2024). EPS: US$0.081 (down from US$52.89 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Primo Brands Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) also missed analyst estimates by 83%. Looking ahead, revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Beverage industry in the US. Performance of the American Beverage industry. The company's shares are down 12% from a week ago. Risk Analysis We should say that we've discovered 2 warning signs for Primo Brands (1 shouldn't be ignored!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
